“Shitstorm” would be one term of art for the reaction in the genome community to a commentary in Cell by Eric Lander, published on January 14. It presents as a definitive account of the discovery of CRISPR, the “gene editing” technique invented in 2013 and which blasted onto the science pages this year. CRISPR is likely to go down as the most important biotechnological invention since Kary Mullis invented the polymerase chain reaction (PCR).
But I prefer another phrase to describe Lander’s account: “Whig history.” The term comes from the Europeanist Herbert Butterfield. In a classic 1931 essay, Butterfield wrote that Whig history was “the tendency in many historians to write [English history] on the side of Protestants and Whigs, to praise revolutions provided they have been successful, to emphasize certain principles of progress in the past and to produce a story which is the ratification if not the glorification of the present.”
The term has become historical shorthand for one way to use history as a political tool. It rationalizes the status quo, wins the allegiance of the establishment, justifies the dominance of those in power. One immediate tip-off to a Whiggish historical account is the use of triumphalist or melodramatic terms such as “heroes” in the title.
Lander’s piece is called “The heroes of CRISPR.”
In April 2014, the Broad Institute at Harvard and MIT—of which Lander is the director— was awarded the first patent for CRISPR technology. The team of Jennifer Doudna (UC Berkeley) and Emmanuelle Charpentier (Umeå University, Sweden) filed their own application seven months earlier, but Zhang obtained fast-track approval. Much remains at stake over CRISPR: fat scientific prizes, almost certainly including a Nobel, as well as further patents. Who claims them will be decided in part by what version of history becomes accepted as “the truth.”
When Michael Eisen, the UC Berkeley/Howard Hughes Medical Institute biologist and astute commentator on genomics read Lander’s article, he went ballistic. In a tweet-blast of righteous indignation, Eisen howled that Lander’s piece minimizes Doudna’s contributions to CRISPR and thus (I’m paraphrasing here) serves as a propaganda organ on behalf of the Broad’s claim to the patent rights. “The whole thing is about trying to establish Zhang paper as pinnacle of CRISPR work,” tweeted Eisen. He continued, “it’s a deliberate effort to undermine Doudna and Charpentier patent claims and prizeworthiness.” It is, he believes, “science propaganda at its most repellent.” “Eric Lander and @broadinstitute should be ashamed of themselves.”
Others have joined in to express their dismay. At the least, many in the community think, some sort of conflict-of-interest statement should have accompanied Lander’s article. A long thread at PubPeer is devoted to the kerfluffle.
Is Eisen right? I’ll leave analysis of the technical arguments over the relative merits of each group’s contributions to the biologists. What I can do is look at the paper itself. Good writers know how rhetoric can be used to persuade. Does Lander use writing techniques to advance a self-interested version of history?
On first read, Lander’s piece seems eminently fair, even generous. It “aims to fill in [the] backstory” of CRISPR, Lander writes; “the history of ideas and the stories of pioneers—and draw lessons about the remarkable ecosystem underlying scientific discovery.” He traces CRISPR’s origins all the way back to Francisco Mojica, a doctoral student at the University of Alicante, in Spain, in 1989. Mojica discovered a new class of repeating sequence that was present in diverse organisms, suggesting widespread taxonomic importance. These, of course, were the first CRISPR sites—clustered regularly-interspaced short palindromic repeats. By 2000, Mojica had found CRISPR loci in 20 different organisms.
By turning his lens on such unsung heroes, laboring away at universities well beyond the anointed labs of Harvard, MIT, UCSF, Johns Hopkins, and the like, Lander creates the impression of inclusiveness, of the sharing of credit among all the “heroes” of CRISPR.
But when he reaches Doudna and Charpentier’s chapter in the story, the generosity becomes curiously muted. Though Lander maintains his warm, avuncular tone, Doudna and Charpentier enter the story as brave soldiers, working shoulder to shoulder with others on the long journey to practical application of CRISPR. Some subtle techniques create a very definite impression.
For example, Lander narrates Charpentier’s story alongside that of the Lithuanian scientist Virginijus Siksnys. But Siksnys receives top billing. His name appears in the first line of two sections of the paper:
Charpentier’s name, on the other hand, appears at the bottom of a paragraph devoted to a component of the CRISPR-cas9 system called tracrRNA.
Jennifer Doudna is graciously given the epithet “world-renowned,” which may distract our attention from the fact that her first mention is buried in the middle of a paragraph, in the second half of a long sentence, the direct object rather than the subject of the sentence:
Doudna and Charpentier go neck and neck with Siksnys through the next sections, but Doudna and Charpentier’s contributions are repeatedly diminished. “Sisknys submitted his paper to Cell on April 6, 2012,” begins one paragraph. It gets rejected without review. He revises and resubmits, to PNAS and appeared online on Sept. 4. The Doudna-Charpentier paper, he writes, “fared better.” He takes care to note that Doudna and Charpentier’s paper was “submitted to Science 2 months after Siksnys’s on June 8.” It “sailed through review,” he writes, and appeared online on June 28. His point: Although Doudna and Charpentier published first, Siksnys submitted his paper weeks before them. Equating the two papers, Lander writes, “both groups clearly recognized the potential for biotechnology.” This clearly undermines Doudna and Charpentier’s claim to invention of the CRISPR-cas9 technology and hence weakens their case for a patent.
Now, enter Feng Zhang and George Church of the Broad Institute. They receive the longest treatment of any actor in the story—a solid page out of nine pages of text. Zhang’s biographical sketch alone receives a long paragraph. Lander is enough of a writer to know that you indicate a character’s importance with the amount of space you devote to them; the longer the bio, the more important the person.
Then Doudna submits a key paper “with assistance from Church.” This and three other “short [ie., minor] papers,” Lander makes sure to note, “were accepted soon after Zhang and Church’s papers were published in early January, 2013.
Lander concludes his saga with words of benevolent wisdom, extolling the “ecology” of science that produces profound discoveries. History provides optimistic lessons about the idealistic world of pure science, carried out purely for the sake of furthering knowledge. One can almost see Lander dabbing away tears of joy as he writes,
The human stories behind scientific advances can teach us a lot about the miraculous ecosystem that drives biomedical progress—about the roles of serendipity and planning, of pure curiosity and practical application, of hypothesis-free and hypothesis-driven science, of individuals and teams, and of fresh perspectives and deep expertise.
So I think Eisen has a point in reading the paper as a crafty effort to establish Zhang and Church as the scientists who brought the relay race to the finish line—and to portray their principal competitors for patents and prizes, Doudna and Charpentier, as merely two in a long string of runners.
I’m glad to see other scientists, such as Mojica, receive credit in a major CRISPR narrative. Too often the early players and the scientists at lesser-known universities become lost to history altogether. But we should also recognize how Lander uses those actors to create a crowd in which to bury Doudna and Charpentier. It would have been possible to mention Mojica, Gilles Vergnaud, and others while still giving Doudna and Charpentier their due.
Why did he do it? The most obvious reason is the patents over the CRISPR technology. The Broad Institute, which Lander directs, is in a heated patent battle with U.C. Berkeley, Doudna’s home. Lander craftily undermines Doudna and Charpentier’s claim to both priority and originality, as well as to the recognition of CRISPR’s commercial potential. Whig history is written by the winners—and sometimes by the competitors.
Update 1/19: Both Doudna and Church have said Lander’s article contains factual errors. I’ll leave it to the experts to debate the technical details of the science. My argument—stimulated and shaped by Eisen’s tweets—is about the tone and style of the piece. Lander is a public-relations master. He’s a compelling speaker and a sophisticated writer. He’s a giant in the field: he has been a leader in the genome community since early days of the human genome project. He knows exactly what he’s doing.
A Nobel can be split at most three ways, and there are four principal actors. How will the prize be partitioned? Doudna, Charpentier, and Zhang? Doudna, Charpentier, and Mojica? Zhang, Church, and Lander? I have witnessed the steady PR campaigns of scientists who went on to win Nobels. The Prize is supposed to be wholly merit-based, but, we being humans, reputation and economics matter.
Update: One should also note the gender dynamics of the story. However conscious or unconscious it may be, efforts such as this underscore the often-subtle ways in which “history by the winners” still tends to end up being “history by the men.” Only way that stops is by saying it out loud. Tip o’ the pin to Anne Fausto-Sterling and Alondra Nelson for nudging me on this.
At its best, science is a model of human interaction: cooperative, open, focused on evidence and reason, unbiased by prejudice of ethnicity, gender, sexuality, or disability. But science is no longer done in monasteries. Competition, pride, ego, greed, and politics play all too great a role in determining who gets credit, who wins the prizes, and who gets into the textbooks. As Butterfield recognized, controlling the history is both a perk of coming out on top and, while the battle still rages, a way to cement your team’s role in the crystallizing master narrative.
When a scientific history promises an account of “heroes,” when it is filled with sentimental language “miraculous ecosystem” of “pure curiosity and practical application,” and when that history is written by an individual who has much to gain by the acceptance of his own account, the piece should come with a conflict-of-interest statement—or at least a road-sign reading, “Danger! Whig history ahead.”
PS: See also Dominic Berry’s take on the Lander article, also drawing on the history of science but framing it in terms of intellectual property, here: http://blogs.sps.ed.ac.uk/engineering-life/2016/01/18/crispr-in-the-history-of-science-and-intellectual-property/
[2017-12-06: Minor edits, mainly typos and style]
20 thoughts on “A Whig History of CRISPR”
“Last spring, the Broad Institute at Harvard and MIT—of which Lander is the director— was awarded the first patent for CRISPR technology.” This patent was awarded in April 14, 2014. US#8,697,359
Right you are. Thanks. Corrected.
At leas the good people at the Breakthrough prize knew and only gave the prize to Charpentier and Doudna.
“… a crafty effort to establish Zhang and Church as the scientists who brought the relay race to the finish line—and to portray their principal competitors for patents and prizes, Doudna and Charpentier, as merely two in a long string of runners.”
This is a mistaken interpretation. It is an effort to establish Zhang as the key scientist, and draw attention to Lander’s Broad Institute. In Lander’s view of history, George Church assisted Zhang, and Doudna was assisted by Church (“a brilliant—and colorful—senior Harvard professor with deep expertise in genomics and synthetic biology who had collaborated with Zhang” […] “Doudna, with assistance from Church…”).
While he mentions a few general things about Church, Lander happens to omit the fact that Church was instrumental in launching the Human Genome Project, a project for which Lander seeks credit despite his belated contribution.
Thanks for your comment. We don’t disagree–those are different aspects of the same overall effort. I agree with you that Lander is trying to bring attention to the Broad. This view is supported by Church’s subsequent statement that Lander showed him the manuscript, Church made corrections of fact, and Lander did not make the changes. I’d love to see Church’s marked up version of the text!
Genotopia, the author, should disclose his or her conflicts. That will make his/her argument stronger and not seem as biased.
I liked the Heros piece as it gave credit for early CRISPR pioneers. The media, including Doudna herself, has been claiming that Doudna “invented” CRISPR. In reality, CRISPR is a natural system whose discovery and characterizations involve dozens of scientists over a couple of decades. The early pioneers should be recognized.
I have no affiliation with any of the parties or institutions involved in this debate.
I agree that the early pioneers deserve credit and say so in the post.
But the CRISPR-cas9 system being used in the lab is not a pure natural system. It is a natural system artfully modified in manifold ways and therefore turned into an engineering tool.
One thing that is important to note is the egregious bias embedded in Figure 2 of the paper. Note how Doudna and Charpentier’s work is colored in red, basically equating it with all the other previous preparatory work, in the second stage of the history, that ultimately leads up to the ground-breaking step 10 (now in a new blue color!) that occurred in Boston. Perhaps even more subtle, Doudna and Charpentier’s work is tagged as step 9, as is the work done in Vilnius, Vienna, and Umea! They don’t even rate a distinct number. All I had to do was look at this picture to see the hidden agenda staring me straight in the face.
Nice. Thanks for adding to the case.
It looks like the nobel prize is already decided then, only question left is who gets it?
That’s the 8 million kroner question!
Focusing on Nobel Prize, there is an often overlooked distinction that it is awarded “for the most important discovery within the domain of physiology or medicine” rather than in Life Sciences in general. IMHO, the works of Barrangou-Moineau-Horvath were the most important ones for the overall advance of human knowledge. RNA-dependent DNA editing was demonstrated there. Yet, due to a more narrow status of the Nobel Prize, this discovery does not qualify, since it is out of the domain of physiology or medicine and more related to microbiology. To test if this system works in mammals (humans) is a more obvious endeavor. Luckily it did. Not surprisingly several groups competed to test it coming into ‘human, all too human’ competition for the Nobel Prize.
A fair and astute point as far as a strict reading of the Prize criteria.
My response would be that historically, the Prize has been given for everything from biotechnology to animal behavior and not rarely has been given to the most celebrated advances rather than the most fundamental. In recent years, it has become increasingly political. I have witnessed multi-year PR campaigns for the Prize, both successful and not. The inventor of dynamite would have spun in his grave over some of the Prizes awarded over the years.
It will be interesting to see if at least one of the early basic researchers (e.g. Mojica) is included when the CRISPR Nobel is awarded.
It is worth noting that Lander, who prides himself as being a computational biologist, has chosen to ignore the computational analysis of the cas genes by Makarova et al. in Nucleic Acids Res. 2002, 30(2):482-496, which predicted functions of various cas genes and identified cas9 (COG3513) as a nuclease. See a totally different take on the whole story at http://irp.nih.gov/catalyst/v24i1/genome-editing
Thanks for this. Funnily enough, that article was written by my neighbor, who told me about it on the bus, the day he interviewed Koonin. He (Koonin) does deserve to be in any complete history of CRISPR.
For an unconventional perspective on Lander’s article, see my comment at PubMed Commons: http://www.ncbi.nlm.nih.gov/pubmed/26771483
A POETIC RESPONSE IN PUBMED
It is good to see history valued in that it has important implications for improving the way science is both published and funded. However, Professor Lander’s history is incomplete and his Panglossian conclusion is questionable.
There are various ways to understand “the human ecosystem that provides scientific advances.” In the 1990s our inexpensive bioinformatic studies of palindromic nucleic sequences and the purine-loading of the loops in stem-loop structures supported our hypothesis of intracellular immunity acted out by RNA molecules that we called “Antibody RNAs” [1-3]. The discovery of the CRISPR systems in bacteria and then similar systems in eukaryotes, made by talented young people close to those with abundant research funds, appeared as welcome support for our hypothesis.
It now appears that the CRISPR discovery endorses “hypothesis free discovery.” But we might have got there much sooner had hypothesis originators better access to research funds. Indeed, the linkage between hypotheses and research agency funding is sadly as fragile as the linkage between breakthrough discovery and editorial acceptance for publication in a high profile journal, as Lander so poignantly relates.
For more please see my poem at PubMed Commons:http://www.ncbi.nlm.nih.gov/pubmed/26771483
 Forsdyke & Mortimer, “Chargaff’s legacy” (2000) Gene 261, 127-137
 Cristillo et al. “Double-stranded RNA as a not-self alarm signal: to evade, most viruses purine-load their RNAs, but some (HTLV-1, Epstein-Barr) pyrimidine-load.” (2001) J Theor Biol 208, 475-491.
 Forsdyke, Madill, Smith, “Immunity as a function of the unicellular state: implications of emerging genomic data.” (2002) Trends Immunol. 23, 575-579.
Sadly, PubMed declined the poem, but PubPeer PubPeer was more obliging.
t is worth noting that Lander, who prides himself as being a computational biologist, has chosen to ignore the computational analysis of the cas genes by Makarova et al.
Comments are closed.